YM155, the small molecule survivin inhibitor, was highly potent in targeting MCL cell lines in vitro and demonstrated significant anti-tumor activity in an aggressive dual resistant B4-derived PDX model. Here, BIRC5 is linked to mantle cell lymphoma.